Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Brief Summary: The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.


Options:
A: Arm Label: Glargine insulin; Type: EXPERIMENTAL; Interventions: Drug: Glargine insulin | Arm Label: NPH insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: NPH insulin | Intervention Type: DRUG; Name: Glargine insulin; Assigned to Arm(s): Glargine insulin | Intervention Type: DRUG; Name: NPH insulin; Assigned to Arm(s): NPH insulin
B: Arm Label: BI 10773 low dose; Type: EXPERIMENTAL; Interventions: Drug: BI 10773 low dose, Drug: Placebo BI 10773 high dose | Arm Label: BI 10773 high dose; Type: EXPERIMENTAL; Interventions: Drug: BI 10773 high dose, Drug: Placebo BI 10773 low dose | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo BI 10773 high dose, Drug: Placebo BI 10773 low dose | Intervention Type: DRUG; Name: BI 10773 low dose; Assigned to Arm(s): BI 10773 low dose | Intervention Type: DRUG; Name: Placebo BI 10773 high dose; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: BI 10773 high dose; Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: Placebo BI 10773 low dose; Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: Placebo BI 10773 low dose; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Placebo BI 10773 high dose; Assigned to Arm(s): BI 10773 low dose
C: Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo
D: Arm Label: Toujeo; Type: EXPERIMENTAL; Interventions: Drug: insulin glargine (U300) | Arm Label: "Standard of care" commercially available basal insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin glargine (U100), Drug: NPH insulin, Drug: insulin detemir, Drug: insulin degludec | Intervention Type: DRUG; Name: insulin glargine (U300); Assigned to Arm(s): Toujeo | Intervention Type: DRUG; Name: insulin glargine (U100); Assigned to Arm(s): "Standard of care" commercially available basal insulin | Intervention Type: DRUG; Name: NPH insulin; Assigned to Arm(s): "Standard of care" commercially available basal insulin | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): "Standard of care" commercially available basal insulin | Intervention Type: DRUG; Name: insulin degludec; Assigned to Arm(s): "Standard of care" commercially available basal insulin

Answer: C